Skip to main
NTHI

NTHI Stock Forecast & Price Target

NTHI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NeOnc Technologies Hldgs is a promising company with a strong focus on developing innovative treatments for CNS tumors. Their lead drugs, NEO212 and NEO100, have shown promising results in clinical trials and have the potential to revolutionize drug delivery to the brain. The company's versatile platform and upcoming data sets make it a strong investment opportunity.

Bears say

NeOnc Technologies Hldgs is developing novel molecular technologies for the targeted delivery of therapeutics into the central nervous system, and has shown early signs of success in clinical data for its lead product candidates, NEO100 and NEO212, in the treatment of glioblastoma. While the company has generated interesting data supporting their drug delivery method, they are a small company with a lot on their plate and face competition from other approaches to CNS delivery. With the market for CNS treatments being highly competitive and NeOnc's limited financial resources, the success of their products hinges on their ability to differentiate themselves through efficacy and safety.

NTHI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neonc Technologies Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neonc Technologies Holdings Inc (NTHI) Forecast

Analysts have given NTHI a Strong Buy based on their latest research and market trends.

According to 3 analysts, NTHI has a Strong Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neonc Technologies Holdings Inc (NTHI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.